Amgen has chalked up a victory in a patent infringement ... and Regeneron recently launched a higher-dose version – called Eylea HD – which requires less frequent injections into the eye.

Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...

Amgen is taking the risky step of preparing to ... high-dose version of Eylea. Eylea HD sales accounted for about $300 million of the franchise total in the second quarter.

Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

Amgen is posting strong growth across its diversified-medicines portfolio. A new weight-loss drug candidate could be a game-changer for the company. Trading at 17 times earnings, the stock offers ...

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming.

To enhance operational efficiency, accuracy and compliance across its highly regulated and complex workflows, leading biopharmaceutical company Amgen Inc. has kickstarted its fully automated dream ...

Oct 22 (Reuters) - Amgen (AMGN.O), opens new tab will launch its biosimilar version of Regeneron's (REGN.O), opens new tab blockbuster eye care drug Eylea following a U.S. appeals court ruling in ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Amgen (AMGN) reports results for the quarter ended September 2024. While this widely-known consensus outlook is ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

Canaccord Genuity analyst John Newman has maintained their bullish stance on REGN stock, giving a Buy rating today. John Newman has given his ...

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based pharma isn’t throwing in the towel just yet. At the same time ...